suPAR assay in clinical routine: evaluation one year after introduction in high automation core lab of the A. Gemelli hospital
By Sonia Flendrich on Thu Apr 27 2023
category: News
ViroGates announces the publication of a new study that shows suPAR causes cardiovascular disease
By ViroGates on Wed Mar 29 2023
Soluble urokinase plasminogen activator receptor and survival in elective cardiac surgery
By Sonia Flendrich on Tue Feb 07 2023
Association between variables measured in the ambulance and in-hospital mortality among adult patients with and without infection: a prospective cohort study
By Nicolaj Toutain on Mon Dec 05 2022
Self‑rated health and chronic infammation are related and independently associated with hospitalization and long‑term mortality in the general population
By Nicolaj Toutain on Mon Nov 28 2022
Soluble Urokinase Plasminogen Activator Receptor Levels and Outcomes in Patients with Heart Failure
By Nicolaj Toutain on Thu Oct 13 2022
Study shows suPAR causes cardiovascular disease
By Nicolaj Toutain on Wed Oct 12 2022
suPAR associates with mortality and improves risk stratification independently of other previously known risk factors in CS patients.
By Nicolaj Toutain on Tue Sep 27 2022
suPAR predicts kidney function decline in patients presenting in the Emergency Department without kidney disease
By Nicolaj Toutain on Tue Sep 20 2022
suPAR as a casual factor in kidney disease – new review summarizes findings
By Nicolaj Toutain on Thu Sep 15 2022
900+
published suPAR studies in leading medical journals
The suPARnostic® brand consists of 4 products:
suPAR is used in clinical routine in 48 hospitals
48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.
New Webinar